Revision of the UWWTD 2024: A Paradigm Shift for the Pharmaceutical Sector
- 1 day ago
- 3 min read
The adoption of Directive (EU) 2024/3019 on urban wastewater treatment (UWWTD), published on 12 December 2024, introduces unprecedented requirements for the pharmaceutical industry. Integrated into the EU “Zero Pollution” Action Plan, this legislation imposes stringent management obligations for pharmaceutical residues, marking a transition from a means-based regulatory framework to one centred on performance obligations and direct financial accountability for pharmaceutical companies.
1. Quaternary Treatment: Removing Organic Micropollutants
The directive’s key technical innovation lies in the mandatory implementation of quaternary treatment to remove micropollutants. Studies indicate that pharmaceutical residues account for approximately 59% of micropollutants detected in urban wastewater.
Performance Requirements and Indicator Substances
The directive establishes a minimum removal rate of 80% for a list of representative indicator substances. These molecules are classified according to their ease of treatment:
Category | Examples of Indicator Substances |
1 : Very easy to treat | Amisulpride, Carbamazepine, Citalopram, Clarithromycin, Diclofenac, Metoprolol, Venlafaxine |
2 : Easy to remove | Benzotriazole, Candesartan, Irbesartan, Mixture of 4- and 5-methylbenzotriazole |
To demonstrate compliance, wastewater treatment plants must monitor at least six substances, with twice as many Category 1 substances as Category 2 substances.
2. Extended Producer Responsibility (EPR): A Major Economic Challenge
To finance these infrastructures, the directive applies the “polluter pays” principle through an Extended Producer Responsibility (EPR) scheme. From 31 December 2028 onwards, pharmaceutical companies will be required to cover at least 80% of the investment and operational costs associated with quaternary treatment and micropollutant monitoring.
Diverging Financial Estimates
The financial impact on the sector remains highly controversial:
European Commission initial estimate: Approximately €130 million per year for France.
(RE)SET study (Leem, FEBEA, GEMME): Estimates the annual burden at between €513 million and €633 million, i.e. four to five times higher than the Commission’s figures.
Despite legal actions brought by industry federations challenging the allegedly disproportionate nature of the measure, the Court of Justice of the European Union (CJEU) dismissed these appeals in February 2026, ruling them inadmissible.
3. Exemption Strategies: The Importance of Biodegradability
Article 9 of the directive defines two mechanisms allowing companies to be exempted from the EPR financial contribution:
Volume threshold criterion: Placing less than 1 tonne per year on the EU market.
Rapid biodegradability: Scientific demonstration that the substance is readily biodegradable in wastewater or does not generate persistent micropollutants at end of life.
The European Commission must establish the detailed technical criteria for these exemptions by 31 December 2027 at the latest. For toxicologists, this highlights the importance of proactively characterising product portfolios to identify eligible substances.
4. Expanded Monitoring: PFAS and Microplastics
Beyond pharmaceuticals, the directive strengthens environmental and public health monitoring obligations. The following are now mandatory:
Monitoring of PFAS (per- and polyfluoroalkyl substances) in influents and effluents of wastewater treatment plants serving more than 10,000 population equivalent (p.e.).
Monitoring of microplastics in sewage sludge, particularly where sludge is reused in agriculture.
Epidemiological surveillance of pathogens such as SARS-CoV-2, influenza viruses, and antimicrobial resistance.
5. Implementation Timeline: The Countdown Has Begun
The rollout of the directive’s obligations follows a phased approach extending to 2045.
Deadline | Major Milestone |
31 July 2027 | Deadline for transposition into French law |
31 December 2027 | Publication of biodegradability criteria and list of substances subject to EPR |
31 December 2028 | Operational launch of EPR financing scheme |
2033 - 2045 | Progressive commissioning of quaternary treatment in UWWTPs |
2045 | 100% of concerned UWWTPs equipped |
Conclusion: Anticipating Change to Control Impact
The 2024 UWWTD introduces a profound transformation of the pharmaceutical industry’s economic model by integrating the aquatic life-cycle costs of products into regulatory obligations. At CEHTRA, we support our partners in the toxicological assessment of their active substances to prepare exemption dossiers and navigate this new EPR framework.
Author: Sophie SIMAR
Looking to assess the impact of the revised UWWTD on your pharmaceutical portfolio?
Contact Sophie Simar to discuss your regulatory strategy, biodegradability assessments, and EPR exemption opportunities.
